Add to my selection

REBLOZYL (luspatercept)

Medicine - Posted on Dec 01 2025

Active substance (DCI)

luspatercept

history (4)

11/5/25

REBLOZYL (luspatercept) - Myelodysplastic syndromes (MDS)

Summary of opinion Favourable opinion for reimbursement only “in adults for the treatment of transfusion-dependent anaemia d...

CAV :
54321

icône flèche
1/22/24

REBLOZYL (luspatercept) - Anémie associée à une bêta-thalassémie

Le laboratoire a informé la HAS de sa demande de non remboursement dans l’indication « Reblozyl est indiqué chez les adultes...

icône flèche
6/16/21

REBLOZYL 25 - (ß-thalassémie) (luspatercept)

Key points Unfavourable opinion for reimbursement in the treatment of adult patients with transfusion-dependent anaemia asso...

icône flèche
6/2/21

REBLOZYL (luspatercept) (syndrome myélodysplasique - SMD)

Key points Favourable opinion for reimbursement in the treatment of adult patients with transfusion-dependent anaemia due to...

CAV :
54321

icône flèche

Technical information

ATC code

B03XA06

Manufacturer

BRISTOL-MYERS SQUIBB

Presentation

REBLOZYL 25 mg, poudre pour solution injectable
1 flacon en verre de 3 ml (CIP : 34009 302 121 4 1)

REBLOZYL 75 mg, poudre pour solution injectable
1 flacon en verre de 3 ml (CIP : 34009 302 121 7 2)

All our publications

Anemia and hemoglobinopathies

Bone marrow diseases

Congenital, genetic and rare diseases